Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Beats Expectations By $0.86 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) posted its earnings results on Tuesday. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86, RTT News reports. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $11.86 EPS.

Regeneron Pharmaceuticals Trading Up 6.2 %

NASDAQ:REGN traded up $41.29 during trading hours on Tuesday, hitting $708.14. The company had a trading volume of 1,111,263 shares, compared to its average volume of 902,338. The company has a market capitalization of $77.82 billion, a PE ratio of 17.53, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The stock has a 50-day moving average price of $719.16 and a 200 day moving average price of $918.90. Regeneron Pharmaceuticals has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday. TD Cowen lowered their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.